{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:40:05Z","timestamp":1791614405573,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute-on-chronic liver failure (ACLF) represents a rising global healthcare burden, characterised by increasing prevalence among patients with decompensated cirrhosis who have a 28-day transplantation-free mortality of 33.9%. Due to disease complexity and a high prevalence of socio-economic disadvantage, there are deficits in quality of care and adherence to guideline-based treatment in this cohort. Compared to other chronic conditions such as heart failure, those with liver disease have reduced access to integrated ambulatory care services. The LivR Well programme is a multidisciplinary intervention aimed at improving 28-day mortality and reducing 30-day readmission through a home-based, liver optimisation programme implemented in the first 28 days after an admission with either ACLF or hepatic decompensation. Outcomes from our feasibility study suggest that the intervention is safe and acceptable to patients and carers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will recruit adult patients with chronic liver disease from the emergency departments, in-patient admissions, and an ambulatory liver clinic of a multi-site quaternary health service in Melbourne, Australia. A total of 120 patients meeting EF-Clif criteria will be recruited to the ACLF arm, and 320 patients to the hepatic decompensation arm. Participants in each cohort will be randomised to the intervention arm, a 28-day multidisciplinary programme or to standard ambulatory care in a 1:1 ratio. The intervention arm includes access to nursing, pharmacy, physiotherapy, dietetics, social work, and neuropsychiatry clinicians. For the ACLF cohort, the primary outcome is 28-day mortality. For the hepatic decompensation cohort, the primary outcome is 30-day re-admission. Secondary outcomes assess changes in liver disease severity and quality of life. An interim analysis will be performed at 50% recruitment to consider early cessation of the trial if the intervention is superior to the control, as suggested in our feasibility study. A cost-effectiveness analysis will be performed. Patients will be followed up for 12 weeks from randomisation. Three exploratory subgroup analyses will be conducted by (a) source of referral, (b) unplanned hospitalisation, and (c) concurrent COVID-19. The trial has been registered with the Australian New Zealand Clinical Trials Registry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study implements a multidisciplinary intervention for ACLF patients with proven benefits in other chronic diseases with the addition of novel digital health tools to enable remote patient monitoring during the COVID-19 pandemic. Our feasibility study demonstrates safety and acceptability and suggests clinical improvement in a small sample size. An RCT is required to generate robust outcomes in this frail, high healthcare resource utilisation cohort with high readmission and mortality risk. Interventions such as LivR Well are urgently required but also need to be evaluated to ensure feasibility, replicability, and scalability across different healthcare systems. The implications of this trial include the generalisability of the programme for implementation across regional and urban centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian New Zealand Clinical Trials Registry (ANZCTR) <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/\">ACTRN12621001703897<\/jats:ext-link>. Registered on 13 December 2021.<\/jats:p>\n                <jats:p>WHO Trial Registration Data Set. See Appendix 1<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06679-x","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:02:34Z","timestamp":1662400954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-3903","authenticated-orcid":false,"given":"Natalie LY","family":"Ngu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Saxby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Worland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Figredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Elford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Seah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tambakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suong","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"4","key":"6679_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jhep.2018.12.018","volume":"70","author":"R Hernaez","year":"2019","unstructured":"Hernaez R, Kramer JR, Liu Y, Tansel A, Natarajan Y, Hussain KB, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: a national cohort study from the USA. J Hepatol. 2019;70(4):639\u201347.","journal-title":"J Hepatol"},{"issue":"7","key":"6679_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426\u201337 37.e1-9.","journal-title":"Gastroenterology"},{"issue":"S2","key":"6679_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jgh.14799","volume":"34","author":"G Lovett","year":"2019","unstructured":"Lovett G, Ha P, Spanidis S, Le S. Health care utilization and cost analysis for decompensated chronic liver disease hospitalizations at a Victorian tertiary health care network: 2009 to 2018. J Gastroenterol Hepatol. 2019;34(S2):52\u2013111.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"6679_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12876-020-01239-6","volume":"20","author":"J Vaz","year":"2020","unstructured":"Vaz J, Eriksson B, Str\u00f6mberg U, Buchebner D, Midl\u00f6v P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol. 2020;20(1):84.","journal-title":"BMC Gastroenterol"},{"key":"6679_CR5","doi-asserted-by":"crossref","unstructured":"Valery PC, McPhail S, Stuart KA, Hartel G, Clark PJ, O'Beirne J, et al. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. Intern Med J. 2020;51(5):691-8.","DOI":"10.1111\/imj.14809"},{"issue":"22","key":"6679_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1056\/NEJMra1914900","volume":"382","author":"V Arroyo","year":"2020","unstructured":"Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382(22):2137\u201345.","journal-title":"N Engl J Med"},{"key":"6679_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eclinm.2019.05.007","volume":"11","author":"EE Powell","year":"2019","unstructured":"Powell EE, Skoien R, Rahman T, Clark PJ, O'Beirne J, Hartel G, et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine. 2019;11:44\u201353.","journal-title":"EClinicalMedicine."},{"issue":"7","key":"6679_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cgh.2013.01.014","volume":"11","author":"AJ Wigg","year":"2013","unstructured":"Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol. 2013;11(7):850\u20138.e1-4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"6679_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1053\/j.gastro.2008.02.001","volume":"134","author":"A O'Brien","year":"2008","unstructured":"O'Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology. 2008;134(6):1729\u201340.","journal-title":"Gastroenterology."},{"key":"6679_CR10","volume-title":"Understanding new models of integrated care in developed countries: a systematic review","author":"S Baxter","year":"2018","unstructured":"Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, Booth A. Understanding new models of integrated care in developed countries: a systematic review; 2018."},{"issue":"1","key":"6679_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12913-021-06262-1","volume":"21","author":"K Dyb","year":"2021","unstructured":"Dyb K, Berntsen GR, Kvam L. Adopt, adapt, or abandon technology-supported person-centred care initiatives: healthcare providers' beliefs matter. BMC Health Serv Res. 2021;21(1):240.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6679_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","volume":"3","author":"SK Sarin","year":"2009","unstructured":"Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL). Hepatol Int. 2009;3(1):269\u201382.","journal-title":"Hepatol Int"},{"key":"6679_CR13","volume-title":"European Foundation for the Study of chronic liver failure","author":"CLIF-C ACLF Calculator","year":"2019","unstructured":"CLIF-C ACLF Calculator. European Foundation for the Study of chronic liver failure; 2019. Available from: https:\/\/www.efclif.com\/scientific-activity\/score-calculators\/clif-c-aclf"},{"issue":"1","key":"6679_CR14","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.jhep.2014.11.045","volume":"62","author":"V Arroyo","year":"2015","unstructured":"Arroyo V, Moreau R, Jalan R, Gin\u00e8s P. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1):S131\u2013S43.","journal-title":"J Hepatol"},{"issue":"s2","key":"6679_CR15","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1046\/j.1440-1746.2000.02124.x","volume":"15","author":"C-J Chen","year":"2000","unstructured":"Chen C-J, Wang L-Y, Yu M-W. Epidemiology of hepatitis B virus infection in the Asia\u2013Pacific region. J Gastroenterol Hepatol. 2000;15(s2):E3\u20136.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"6679_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","volume":"58","author":"M Blachier","year":"2013","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593\u2013608.","journal-title":"J Hepatol"},{"issue":"3","key":"6679_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"6679_CR18","doi-asserted-by":"publisher","first-page":"i5239","DOI":"10.1136\/bmj.i5239","volume":"355","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.","journal-title":"BMJ."},{"key":"6679_CR19","unstructured":"Welcome and overview of Monash Health Melbourne, Victoria, Australia: Monash Health; 2020 [Available from: https:\/\/monashhealth.org\/employees\/student-orientation\/welcome-and-overview-of-monash-health\/."},{"key":"6679_CR20","unstructured":"Quality Account 2018-19. Melbourne, Victoria, Australia: Monash Health; 2019."},{"issue":"2","key":"6679_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"easloffice@easloffice.eu EAftSotLEa, Liver EAftSot","year":"2018","unstructured":"easloffice@easloffice.eu EAftSotLEa, Liver EAftSot. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u201360.","journal-title":"J Hepatol"},{"issue":"4","key":"6679_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.","journal-title":"Age Ageing"},{"issue":"3","key":"6679_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1741-6612.2009.00375.x","volume":"28","author":"C Stapleton","year":"2009","unstructured":"Stapleton C, Hough P, Oldmeadow L, Bull K, Hill K, Greenwood K. Four-item fall risk screening tool for subacute and residential aged care: the first step in fall prevention. Australas J Ageing. 2009;28(3):139\u201343.","journal-title":"Australas J Ageing"},{"issue":"3","key":"6679_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0261-5614(02)00214-5","volume":"22","author":"J Kondrup","year":"2003","unstructured":"Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Group AHEW. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321\u201336.","journal-title":"Clin Nutr"},{"issue":"5","key":"6679_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"2","key":"6679_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gut.45.2.295","volume":"45","author":"ZM Younossi","year":"1999","unstructured":"Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295\u2013300.","journal-title":"Gut."},{"issue":"Pt 2","key":"6679_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1258\/acb.2011.011115","volume":"49","author":"NE Walsham","year":"2012","unstructured":"Walsham NE, Sherwood RA. Ethyl glucuronide. Ann Clin Biochem. 2012;49(Pt 2):110\u20137.","journal-title":"Ann Clin Biochem"},{"key":"6679_CR28","unstructured":"Safety monitoring and reporting in clinical trials involving therapeutic foods. In: Administration TG, editor.: Australian Government; 2016. p. 5."},{"issue":"2","key":"6679_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ajg.2011.314","volume":"107","author":"ML Volk","year":"2012","unstructured":"Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107(2):247\u201352.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"6679_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hep4.1472","volume":"4","author":"S Chirapongsathorn","year":"2020","unstructured":"Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi K, Treeprasertsuk S. Thirty-day readmission and cost analysis in patients with cirrhosis: a Nationwide population-based data. Hepatol Commun. 2020;4(3):453\u201360.","journal-title":"Hepatol Commun"},{"issue":"5","key":"6679_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479\u2013500.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"6679_CR32","first-page":"810","volume":"44","author":"FA McAlister","year":"2004","unstructured":"McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44(4):810\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"6679_CR33","doi-asserted-by":"crossref","unstructured":"Wigg AJ, Chin JK, Muller KR, Ramachandran J, Woodman RJ, Kaambwa B. Cost-effectiveness of a chronic disease management model for cirrhosis: analysis of a randomized controlled trial. J Gastroenterol Hepatol. 2018.","DOI":"10.1111\/jgh.14127"},{"issue":"7","key":"6679_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5694\/mja17.01164","volume":"209","author":"J Ramachandran","year":"2018","unstructured":"Ramachandran J, Hossain M, Hrycek C, Tse E, Muller KR, Woodman RJ, et al. Coordinated care for patients with cirrhosis: fewer liver-related emergency admissions and improved survival. Med J Aust. 2018;209(7):301\u20135.","journal-title":"Med J Aust"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06679-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:23:21Z","timestamp":1662402201000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6679"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06679-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval has been obtained through the Monash Health Human Research Ethics Committee under an existing approval for The Virtual Hospital.Registration: QA\/76264\/MonH-2021-265874(v1)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for participation and future publication using a Participant Information and Consent Form (PICF) as a sub-study of The Virtual Hospital, a \u201cdigital health ecosystem supporting mobile person-centred care for chronic conditions\u201d (Appendix ). Written, informed consent will be obtained at the first liver clinic appointment, scheduled within 7 days of admission. The consent process will be performed by a sub-investigator. Language interpreters will be used when required. Consent can be withdrawn at any time. Intention-to-treat analysis will be utilised to account for dropout.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"744"}}